No change in health-related quality of life for at-risk U.S. women and men starting HIV pre-exposure prophylaxis (PrEP): Findings from HPTN 069/ACTG A5305.

by Shashi N Kapadia, Chunyuan Wu, Kenneth H Mayer, Timothy J Wilkin, K Rivet Amico, Raphael J Landovitz, Adriana Andrade, Ying Q Chen, Wairimu Chege, Marybeth McCauley, Roy M Gulick, Bruce R Schackman
Published 2018-01-01

Association of HIV diversity and virologic outcomes in early antiretroviral treatment: HPTN 052.

by Philip J Palumbo, Ethan A Wilson, Estelle Piwowar-Manning, Marybeth McCauley, Theresa Gamble, Newton Kumwenda, Joseph Makhema, Nagalingeswaran Kumarasamy, Suwat Chariyalertsak, James G Hakim, Mina C Hosseinipour, Marineide G Melo, Sheela V Godbole, Jose H Pilotto, Beatriz Grinsztejn, Ravindre Panchia, Ying Q Chen, Myron S Cohen, Susan H Eshleman, Jessica M Fogel
Published 2017-01-01

Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial.

by Raphael J Landovitz, Sue Li, Beatriz Grinsztejn, Halima Dawood, Albert Y Liu, Manya Magnus, Mina C Hosseinipour, Ravindre Panchia, Leslie Cottle, Gordon Chau, Paul Richardson, Mark A Marzinke, Craig W Hendrix, Susan H Eshleman, Yinfeng Zhang, Elizabeth Tolley, Jeremy Sugarman, Ryan Kofron, Adeola Adeyeye, David Burns, Alex R Rinehart, David Margolis, William R Spreen, Myron S Cohen, Marybeth McCauley, Joseph J Eron
Published 2018-11-01